BRAF and neoplasm: Most studies in mCRC have reported good concordance in mutational profiles of major signaling pathways, such as KRAS, TP53, APC, PIK3CA, BRAF, and NRAS, between the primary tumor and its metastases, superior to 95% [72,73].